{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:52:05Z","timestamp":1794095525916,"version":"4.8.0"},"reference-count":78,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,2,11]]},"DOI":"10.1001\/jama.2019.22360","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:01:09Z","timestamp":1581418869000},"page":"548","source":"Crossref","is-referenced-by-count":2897,"title":["Diagnosis and Treatment of Parkinson Disease"],"prefix":"10.1001","volume":"323","author":[{"given":"Melissa J.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Florida College of Medicine, Gainesville"},{"name":"Fixel Institute for Neurologic Diseases, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Florida College of Medicine, Gainesville"},{"name":"Fixel Institute for Neurologic Diseases, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"jrv190013r1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"key":"jrv190013r2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson\u2019s disease across North America.","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"jrv190013r5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/amiajnl-2012-001075","article-title":"MEDLINE clinical queries are robust when searching in recent publishing years.","volume":"20","author":"Wilczynski","year":"2013","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"jrv190013r7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease.","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"3","key":"jrv190013r8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/brain\/awx376","article-title":"Progression of tremor in early stages of Parkinson\u2019s disease: a clinical and neuroimaging study.","volume":"141","author":"Pasquini","year":"2018","journal-title":"Brain"},{"issue":"10","key":"jrv190013r9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/ene.2017.24.issue-10","article-title":"The role of neurotransmitters in the development of Parkinson\u2019s disease\u2013related psychosis.","volume":"24","author":"Factor","year":"2017","journal-title":"Eur J Neurol"},{"issue":"7","key":"jrv190013r10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease.","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"Pt 9","key":"jrv190013r11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease.","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"key":"jrv190013r12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.02.017","article-title":"Overview of the cholinergic contribution to gait, balance and falls in Parkinson\u2019s disease.","volume":"63","author":"Morris","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"jrv190013r13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mds.22868","article-title":"The nondeclaration of nonmotor symptoms of Parkinson\u2019s disease to health care professionals: an international study using the nonmotor symptoms questionnaire.","volume":"25","author":"Chaudhuri","year":"2010","journal-title":"Mov Disord"},{"issue":"12","key":"jrv190013r14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease.","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"key":"jrv190013r15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies.","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med Rev"},{"issue":"6","key":"jrv190013r16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jamaneurol.2014.4563","article-title":"Rapid eye movement sleep behavior disorder and neurodegenerative disease.","volume":"72","author":"Howell","year":"2015","journal-title":"JAMA Neurol"},{"issue":"Pt 5","key":"jrv190013r17","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity.","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"issue":"2","key":"jrv190013r18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","article-title":"A clinicopathologic study of 100 cases of Parkinson\u2019s disease.","volume":"50","author":"Hughes","year":"1993","journal-title":"Arch Neurol"},{"issue":"12","key":"jrv190013r19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"3","key":"jrv190013r20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"jrv190013r21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","article-title":"The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson\u2019s disease or clinically uncertain parkinsonism: a systematic review.","volume":"5","author":"Suwijn","year":"2015","journal-title":"EJNMMI Res"},{"issue":"3","key":"jrv190013r22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14737175.2017.1256205","article-title":"Clinical utility of DaTscan\u2122 imaging in the evaluation of patients with parkinsonism: a US perspective.","volume":"17","author":"Isaacson","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"jrv190013r23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.","volume":"84","author":"Bajaj","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"jrv190013r24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11910-019-0964-5","article-title":"Structural imaging in Parkinson\u2019s disease: new developments.","volume":"19","author":"Prange","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"jrv190013r25","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/awx146","article-title":"Progression marker of Parkinson\u2019s disease: a 4-year multi-site imaging study.","volume":"140","author":"Burciu","year":"2017","journal-title":"Brain"},{"issue":"5","key":"jrv190013r26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.parkreldis.2012.01.009","article-title":"123I-MIBG myocardial scintigraphy for differentiating Parkinson\u2019s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.","volume":"18","author":"Orimo","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"jrv190013r27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11910-017-0738-x","article-title":"Subtypes of Parkinson\u2019s disease: what do they tell us about disease progression?","volume":"17","author":"Fereshtehnejad","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"jrv190013r28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaneurol.2013.6233","article-title":"Parkinson disease subtypes.","volume":"71","author":"Thenganatt","year":"2014","journal-title":"JAMA Neurol"},{"issue":"7","key":"jrv190013r29","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression.","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"issue":"12","key":"jrv190013r30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression.","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"jrv190013r31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mds.23346","article-title":"Clinical subtypes of Parkinson\u2019s disease.","volume":"26","author":"van Rooden","year":"2011","journal-title":"Mov Disord"},{"issue":"4","key":"jrv190013r32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","article-title":"Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease.","volume":"76","author":"De Pablo-Fern\u00e1ndez","year":"2019","journal-title":"JAMA Neurol"},{"issue":"13","key":"jrv190013r33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/mds.v29.13","article-title":"Mortality in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"29","author":"Macleod","year":"2014","journal-title":"Mov Disord"},{"issue":"6","key":"jrv190013r34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years.","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"key":"jrv190013r35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2017.05.022","article-title":"Death certificate data and causes of death in patients with parkinsonism.","volume":"41","author":"Moscovich","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"jrv190013r36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.parkreldis.2010.04.010","article-title":"The cause of death in idiopathic Parkinson\u2019s disease.","volume":"16","author":"Pennington","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"jrv190013r37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","article-title":"The spectrum of \u201coff\u201d in Parkinson\u2019s disease: what have we learned over 40 years?","volume":"51","author":"Chou","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 10","key":"jrv190013r38","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa.","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"issue":"6","key":"jrv190013r39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts.","volume":"84","author":"Espay","year":"2018","journal-title":"Ann Neurol"},{"issue":"24","key":"jrv190013r40","doi-asserted-by":"publisher","first-page":"e2238","DOI":"10.1212\/WNL.0000000000006643","article-title":"Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study.","volume":"91","author":"Turcano","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"jrv190013r41","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","article-title":"The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort.","volume":"84","author":"Williams-Gray","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"jrv190013r42","article-title":"Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study (CEPA Study).","volume":"2017","author":"Luquin","year":"2017","journal-title":"Parkinsons Dis"},{"issue":"8","key":"jrv190013r43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease.","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"issue":"6","key":"jrv190013r44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamaneurol.2017.0348","article-title":"Common myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice.","volume":"74","author":"Espay","year":"2017","journal-title":"JAMA Neurol"},{"issue":"9949","key":"jrv190013r45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial.","volume":"384","author":"Gray","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"jrv190013r46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study.","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"jrv190013r47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease.","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"jrv190013r48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.","volume":"84","author":"Pondal","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"jrv190013r49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1590\/0004-282x20180140","article-title":"Apomorphine in the treatment of Parkinson\u2019s disease: a review.","volume":"76","author":"Pessoa","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"jrv190013r50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol"},{"issue":"8","key":"jrv190013r51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial.","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"issue":"11","key":"jrv190013r53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrneurol.2017.128","article-title":"Long-term effects of exercise and physical therapy in people with Parkinson disease.","volume":"13","author":"Mak","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"jrv190013r54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0269215515570381","article-title":"Effectiveness of resistance training on muscle strength and physical function in people with Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"30","author":"Chung","year":"2016","journal-title":"Clin Rehabil"},{"issue":"5","key":"jrv190013r55","first-page":"704","article-title":"Treadmill training for patients with Parkinson disease: an abridged version of a Cochrane Review.","volume":"52","author":"Mehrholz","year":"2016","journal-title":"Eur J Phys Rehabil Med"},{"issue":"9","key":"jrv190013r56","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s10072-017-3020-8","article-title":"Can music-based movement therapy improve motor dysfunction in patients with Parkinson\u2019s disease? systematic review and meta-analysis.","volume":"38","author":"Zhang","year":"2017","journal-title":"Neurol Sci"},{"key":"jrv190013r57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12883-015-0484-0","article-title":"Argentine tango in Parkinson disease\u2014a systematic review and meta-analysis.","volume":"15","author":"L\u00f6tzke","year":"2015","journal-title":"BMC Neurol"},{"issue":"7","key":"jrv190013r58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102942","article-title":"Tai Chi for improvement of motor function, balance and gait in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"jrv190013r59","article-title":"Physiotherapy versus placebo or no intervention in Parkinson\u2019s disease.","volume":"9","author":"Tomlinson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"jrv190013r60","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1212\/WNL.0000000000002670","article-title":"Quality improvement in neurology: Parkinson disease update quality measurement set: executive summary.","volume":"86","author":"Factor","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"jrv190013r61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the Unified Parkinson's Disease Rating Scale.","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch Neurol"},{"issue":"10","key":"jrv190013r62","article-title":"Efficacy and safety of deep brain stimulation in the treatment of parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"10","author":"Bratsos","year":"2018","journal-title":"Cureus"},{"issue":"12","key":"jrv190013r63","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial.","volume":"74","author":"Bond","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"jrv190013r64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00415-015-7942-x","article-title":"Referring Parkinson\u2019s disease patients for deep brain stimulation: a RAND\/UCLA appropriateness study.","volume":"263","author":"Moro","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"jrv190013r65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1212\/01.WNL.0000133122.14824.25","article-title":"Development and initial validation of a screening tool for Parkinson disease surgical candidates.","volume":"63","author":"Okun","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"jrv190013r66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00415-010-5814-y","article-title":"A tool to improve pre-selection for deep brain stimulation in patients with Parkinson\u2019s disease.","volume":"258","author":"W\u00e4chter","year":"2011","journal-title":"J Neurol"},{"key":"jrv190013r67","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fneur.2018.00620","article-title":"Levodopa-carbidopa intestinal gel in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"9","author":"Wang","year":"2018","journal-title":"Front Neurol"},{"issue":"5","key":"jrv190013r68","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-016-0336-5","article-title":"Levodopa-carbidopa intestinal gel in patients with Parkinson\u2019s disease: a systematic review.","volume":"30","author":"Wirdefeldt","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"jrv190013r69","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.v34.2","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review.","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"24","key":"jrv190013r70","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease.","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv190013r71","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with parkinson disease.","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol"},{"issue":"11","key":"jrv190013r72","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1248\/bpb.b17-00602","article-title":"Comparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis.","volume":"40","author":"Iketani","year":"2017","journal-title":"Biol Pharm Bull"},{"issue":"9916","key":"jrv190013r73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial.","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"jrv190013r74","article-title":"Interventions for fatigue in Parkinson\u2019s disease.","volume":"10","author":"Elbers","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"jrv190013r75","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1517\/14656566.2015.1086747","article-title":"The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson\u2019s disease.","volume":"16","author":"Barboza","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"jrv190013r76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson\u2019s disease: a review.","volume":"20","author":"Srivanitchapoom","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"jrv190013r77","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1212\/WNL.0000000000000674","article-title":"Palliative care and neurology: time for a paradigm shift.","volume":"83","author":"Boersma","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"jrv190013r78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/jamaneurol.2017.3517","article-title":"Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial.","volume":"75","author":"Schenkman","year":"2018","journal-title":"JAMA Neurol"},{"key":"jrv190013r3","volume-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects [Internet]","author":"Kouli","year":"2018"},{"key":"jrv190013r4","unstructured":"International Parkinson and Movement Disorder Society. Evidence Based Medicine Publications.https:\/\/www.movementdisorders.org\/MDS\/Resources\/Publications-Reviews\/EBM-Reviews.htm. Accessed November 14, 2019."},{"key":"jrv190013r6","unstructured":"US National Library of Medicine. Search strategy used to create the PubMed systematic reviews filter.https:\/\/www.nlm.nih.gov\/bsd\/pubmed_subsets\/sysreviews_strategy.html. Updated December 2018. Accessed September 6, 2019."},{"key":"jrv190013r52","unstructured":"Vertical Pharmaceuticals. Osmolex ER prescribing information. 2018. https:\/\/www.osmolexhcp.com\/images\/pdf\/Prescribing_Information.pdf. Accessed July 29, 2019."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2760741\/jama_armstrong_2020_rv_190013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:01:15Z","timestamp":1581418875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2760741"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.22360","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737357418.793578807","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}